822 related articles for article (PubMed ID: 26018927)
1. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.
Visuri MT; Honkonen KM; Hartiala P; Tervala TV; Halonen PJ; Junkkari H; Knuutinen N; Ylä-Herttuala S; Alitalo KK; Saarikko AM
Angiogenesis; 2015 Jul; 18(3):313-26. PubMed ID: 26018927
[TBL] [Abstract][Full Text] [Related]
2. Lymph node transfer and perinodal lymphatic growth factor treatment for lymphedema.
Honkonen KM; Visuri MT; Tervala TV; Halonen PJ; Koivisto M; Lähteenvuo MT; Alitalo KK; Ylä-Herttuala S; Saaristo AM
Ann Surg; 2013 May; 257(5):961-7. PubMed ID: 23013803
[TBL] [Abstract][Full Text] [Related]
3. Growth factor therapy and lymph node graft for lymphedema.
Tervala TV; Hartiala P; Tammela T; Visuri MT; Ylä-Herttuala S; Alitalo K; Saarikko AM
J Surg Res; 2015 Jun; 196(1):200-7. PubMed ID: 25777822
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
5. Lymphangiogenic growth factors, receptors and therapies.
Lohela M; Saaristo A; Veikkola T; Alitalo K
Thromb Haemost; 2003 Aug; 90(2):167-84. PubMed ID: 12888864
[TBL] [Abstract][Full Text] [Related]
6. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
Lohela M; Heloterä H; Haiko P; Dumont DJ; Alitalo K
Am J Pathol; 2008 Dec; 173(6):1891-901. PubMed ID: 18988807
[TBL] [Abstract][Full Text] [Related]
7. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
Rissanen TT; Markkanen JE; Gruchala M; Heikura T; Puranen A; Kettunen MI; Kholová I; Kauppinen RA; Achen MG; Stacker SA; Alitalo K; Ylä-Herttuala S
Circ Res; 2003 May; 92(10):1098-106. PubMed ID: 12714562
[TBL] [Abstract][Full Text] [Related]
8. Utilization of Vascular Endothelial Growth Factor-C156S in Therapeutic Lymphangiogenesis: A Systematic Review.
Forte AJ; Boczar D; Huayllani MT; Anastasiadis PZ; McLaughlin S
Lymphat Res Biol; 2022 Dec; 20(6):580-584. PubMed ID: 35501971
[No Abstract] [Full Text] [Related]
9. Extracorporeal shock wave therapy combined with vascular endothelial growth factor-C hydrogel for lymphangiogenesis.
Kim IG; Lee JY; Lee DS; Kwon JY; Hwang JH
J Vasc Res; 2013; 50(2):124-33. PubMed ID: 23208012
[TBL] [Abstract][Full Text] [Related]
10. Lymphangiogenic gene therapy with minimal blood vascular side effects.
Saaristo A; Veikkola T; Tammela T; Enholm B; Karkkainen MJ; Pajusola K; Bueler H; Ylä-Herttuala S; Alitalo K
J Exp Med; 2002 Sep; 196(6):719-30. PubMed ID: 12235206
[TBL] [Abstract][Full Text] [Related]
11. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
[TBL] [Abstract][Full Text] [Related]
12. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
13. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
14. Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1.
Jha SK; Rauniyar K; Karpanen T; Leppänen VM; Brouillard P; Vikkula M; Alitalo K; Jeltsch M
Sci Rep; 2017 Jul; 7(1):4916. PubMed ID: 28687807
[TBL] [Abstract][Full Text] [Related]
15. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
Syväranta S; Helske S; Lappalainen J; Kupari M; Kovanen PT
Atherosclerosis; 2012 Apr; 221(2):366-74. PubMed ID: 22281299
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.
Karkkainen MJ; Haiko P; Sainio K; Partanen J; Taipale J; Petrova TV; Jeltsch M; Jackson DG; Talikka M; Rauvala H; Betsholtz C; Alitalo K
Nat Immunol; 2004 Jan; 5(1):74-80. PubMed ID: 14634646
[TBL] [Abstract][Full Text] [Related]
18. Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S.
Bhansali SG; Balu-Iyer SV; Morris ME
J Pharm Sci; 2012 Feb; 101(2):852-9. PubMed ID: 22030745
[TBL] [Abstract][Full Text] [Related]
19. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins.
Tammela T; He Y; Lyytikkä J; Jeltsch M; Markkanen J; Pajusola K; Ylä-Herttuala S; Alitalo K
Circ Res; 2007 May; 100(10):1468-75. PubMed ID: 17478733
[TBL] [Abstract][Full Text] [Related]
20. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation.
Karpanen T; Wirzenius M; Mäkinen T; Veikkola T; Haisma HJ; Achen MG; Stacker SA; Pytowski B; Ylä-Herttuala S; Alitalo K
Am J Pathol; 2006 Aug; 169(2):708-18. PubMed ID: 16877368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
